| Imaging of the aortic root | |
| Perioperative imaging for assessing aortic and mitral valve diseases and surgical procedures | p. 3 |
| Innovations in aortic valve surgery | |
| The aortic root | p. 13 |
| Percutaneous transluminal aortic valve replacement: The CoreValve prosthesis | p. 22 |
| Transapical aortic valve implantation - a truly minimally invasive option for high-risk patients | p. 32 |
| From minimally invasive to percutaneous aortic valve replacement | p. 46 |
| Sutureless equine aortic valve replacement | p. 57 |
| The Ross operation: Aortic valve and root replacement with pulmonary autograft | |
| Pulmonary autograft or aortic allograft for surgical treatment of active infective aortic valve endocarditis: a review of the literature | p. 67 |
| The Ross operation: two decades of clinical experience | p. 74 |
| Aortic valve repair and valve sparing root procedures | |
| The bicuspid aortic valve | p. 89 |
| From dynamic anatomy to conservative aortic valve surgery: the tale of the ring | p. 102 |
| Yacoub/David techniques for aortic root operation: success and failures | p. 133 |
| Aortic annuloplasty | p. 144 |
| Correction of aortic valve incompetence combined with ascending aortic aneurysm by relocation of the aortic valve plane through a short-length aortic graft replacement | p. 178 |
| Using BioGlue to achieve hemostasis in aortic root surgery | p. 185 |
| Endocarditis | |
| Challenges in the surgical management of infective endocarditis | p. 195 |
| Clinical results of the Shelhigh“ stentless bioprosthesis in patients with active infective endocarditis: 8-year single center experience | p. 210 |
| Double valve endocarditis and evolving paraannular abscess formation | p. 223 |
| Aortic root abscess: reconstruction of the left ventricular outflow tract and allograft aortic valve and root replacement | p. 243 |
| Implantation techniques of freehand subcoronary aortic valve and root replacement with a cryopreserved allograft for aortic root abscess | |
| Surgery for atrial fibrillation | |
| Cryoablation for the treatment of atrial fibrillation in patients undergoing minimally invasive mitral valve surgery - Technique and recent results | p. 291 |
| Minimally invasive endoscopic ablation on the beating heart in patients with lone atrial fibrillation | p. 302 |
| Hemodynamic evaluation of the bioprosthetic aortic valves | |
| Evaluation of bioprosthetic valve performance as a function of geometric orifice area and space efficiency - a reliable alternative to effective orifice area | p. 313 |
| Long-term results of biological valves | |
| Stentless bioprostheses | |
| Stented and stentless aortic bioprostheses: competitive or complimentary? | p. 341 |
| Edwards Prima Plus Stentless Bioprosthesis: long-term clinical and hemodynamic results | p. 346 |
| The Cryo-Life O'Brian stentless valve: 1991-2008 | p. 356 |
| Medtronic stentless Freestyle“ porcine aortic valve replacement | p. 366 |
| The ATS 3f Aortic Bioprosthesis | p. 386 |
| The Vascutek Elan stentless porcine prosthesis - the Glasgow experience | p. 396 |
| Sorin pericardial valves - Operative technique and early results of biological valves | p. 406 |
| Stented bioprostheses | |
| The changing role of pericardial tissue in biological valve surgery: 22 years' experience with the Sorin Mitroflow stented pericardial valve | p. 417 |
| 20 years' durability of Carpentier-Edwards Perimount stented pericardial aortic valve | p. 441 |
| Twenty-year experience with the St. Jude Medical Biocor bioprosthesis in the aortic position | p. 452 |
| 20-Year durability of bioprostheses in the aortic position | p. 463 |
| Clinical results including hemodynamic performance of the Medtronic Mosaic porcine bioprosthesis up to ten years | p. 470 |
| Aortic root replacement with the Bio Valsalva prosthesis | p. 487 |
| Valve replacement in renal dialysis patients: bioprostheses versus mechanical prostheses | p. 498 |
| Replacement of bioprostheses after structural valve deterioration | p. 503 |
| Predictors of patient's outcome | |
| Predicted outcomes after aortic valve replacement in octogenarians with aortic stenosis | p. 523 |
| Predicted patient outcome after bioprosthetic AVR and the Ross operation | p. 530 |
| Anticoagulation | |
| Anticoagulation and self-management of INR: mid-term results | p. 541 |
| Tissue engineering | |
| Biomatrix-polymer hybrid material for heart valve tissue engineering | p. 551 |
| Standards for the in vitro fabrication of heart valves using human umbilical cord cells | p. 564 |
| Tissue engineering with a decellularized valve matrix | p. 574 |
| Regularatory issues on tissue valves | |
| Human tissues for cardiovascular surgery: regulatory requirements | p. 581 |
| Concluding remarks | p. 588 |
| Acknowledgments | p. 590 |
| Atlas of biological valves | p. 591 |
| Subject index | p. 599 |
| Table of Contents provided by Ingram. All Rights Reserved. |
